表紙
市場調査レポート

バイオシミラーの世界市場の見通し (2020年まで)

Global Biosimilar Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 296320
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
バイオシミラーの世界市場の見通し (2020年まで) Global Biosimilar Market Outlook 2020
出版日: 2015年04月01日 ページ情報: 英文 110 Pages
概要

米国では長年にわたり待ち望まれていたG-CSF (顆粒球コロニー刺激因子) の一種、Zarxio (Sandoz社) が上市されました。他のバイオシミラー・メーカーもこの動きを歓迎しており、自社製品の申請・上市へと動くものと見られ、米国のバイオシミラー市場は今後大幅に活発化すると期待されています。一方で、予算削減に伴って医療費支出が縮小しており、ブロックバスター薬の売上高も大幅に落ち込む中で、バイオシミラー市場は拡大傾向を保っています。全世界のバイオシミラーの市場規模は、2014年の18億9000万米ドルから、2020年には255億3000万米ドルまで、54.4%もの年平均成長率 (CAGR) で拡大する、と予測されています。

当レポートでは、世界のバイオシミラー市場について調査分析し、市場動向と促進要因、市場の見通し、地域分析、資本取引の動向を提供するほか、主要企業プロファイルなどの情報を盛り込んでお届けいたします。

第1章 アナリストの見解

第2章 調査手法

第3章 生物製剤市場の見通し

  • 市場規模
  • 市場区分

第4章 世界のバイオシミラー市場の見通し

  • 市場規模
  • 市場区分および用途
    • エリスロポエチン (EPO)
    • ヒト成長ホルモン (HGH)
    • 顆粒球コロニー刺激因子 (G-CSF)
    • モノクローナル抗体 (mAb)
    • インスリン
    • インターフェロン (IFN)
  • 地域別の市場区分
    • 欧州
    • アジア太平洋地域
    • その他

第5章 市場の促進要因と課題

  • 促進要因
    • 米国での最初のバイオシミラー認証が、高収益市場への道を拓く
    • 医療予算の縮小が、バイオシミラー市場の前進につながる
    • 多数の生物製剤の特許満了により、バイオシミラーの市場機会が誕生する
  • 課題
    • 製造能力の開発の必要性
    • 訴訟リスクの上昇
    • 多額の開発費用と低い普及率
    • 互換性/代替性

第6章 市場の傾向と発展

  • プラントベースのバイオシミラー製造プラットフォーム
  • 発展途上国が、バイオシミラーの新たな生産拠点として浮上

第7章 企業合併・買収 (M&A)

第8章 ポーターのファイブフォース分析

第9章 競合情勢

  • 主要企業の市場シェア
  • プロファイル
    • Biocad
    • Celltrion
    • Dong-A Pharmaceutical Co., Ltd
    • Hospira
    • Intas
    • Sandoz
    • Stada Arzneimittel
    • Teva

第10章 将来の見通し

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz's Zarxio, a G-CSF. The move is being hailed by biosimilar manufacturers and is expected to fuel numerous submissions in the coming days, making US a significant region for biosimilar activity. At the same time, as shrinking budgets are rooting for reduced healthcare expenditures and majority of blockbuster drugs are about to lose exclusivity, the biosimilar industry stands as the sole gainer.

A new research study conducted by RNCOS, “Global Biosimilar Market Outlook 2020”, reveals that the market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR of 54.4%. The report has been divided into numerous sections that deal with the various aspects of the market.

In the report, industry has been segmented based on the different classes of biosimilars available in the market, such as, mAbs, Insulin, Erythropoeitin (EPOs), Human Growth Hormone (HGH) and Interferons. The second segmentation divides the industry on the basis of major geographies which includes Europe, Asia-Pacific, and Others (including the US, Latin America and Middle-Eastern countries).

The market is subjected to various drivers as well as challenges, which have, and will continue to mould it. It is expected that the constricting healthcare budgets, approaching patent cliff and low cost of biosimilars will serve as the major drivers for the market. However, issues associated with manufacturing capabilities, litigation risks, high cost of development and substitutability may act as bottlenecks for the industry. The report talks about the various applications and technological trends that have emerged in the past few years.

This report also highlights key players and their current market share in the biosimilar domain. For every player, a brief business overview, geographic revenue break up, segment wise revenue break up, along with key financials, have been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of the players. At the end, a section has been dedicated to the future outlook. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the biosimilars industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2020

  • 3.1. Market Size
  • 3.2. Market Segmentation

4. Global Biosimilars Market Outlook 2020

  • 4.1. Market Size
  • 4.2. Market Segmentation by Application
    • 4.2.1. Erythropoietin (EPO)
    • 4.2.2. Human Growth Hormone (HGH)
    • 4.2.3. Granulocyte- Colony Stimulating Factor (G-CSF)
    • 4.2.4. Monoclonal Antibody (mAb)
    • 4.2.5. Insulin
    • 4.2.6. Interferon (IFN)
  • 4.3. Market Segmentation by Geography
    • 4.3.1. Europe
    • 4.3.2. Asia-Pacific
    • 4.3.3. Others

5. Market Drivers and Challenges

  • 5.1. Drivers
    • 5.1.1. Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
    • 5.1.2. Shrinking Healthcare Budgets to Carve Way for Biosimilars
    • 5.1.3. Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
  • 5.2. Challenges
    • 5.2.1. Need for the Development of Manufacturing Capabilities
    • 5.2.2. Greater Litgation Risk
    • 5.2.3. High Cost of Development Accompanied with Low Adoption
    • 5.2.4. Interchangeability/ Substitutability

6. Market Trends and Developments

  • 6.1. Plant based Manufacturing Platforms for Biosimilars
  • 6.2. Developing Economies Emerge as Potential Markets for Biosimilar Production

7. Mergers and Acquisitions

8. Porter's Analysis

9. Competitive Landscape

  • 9.1. Market Share of Major Players
  • 9.2. Profiles
    • 9.2.1. Biocad
    • 9.2.2. Celltrion
    • 9.2.3. Dong-A Pharmaceutical Co., Ltd
    • 9.2.4. Hospira
    • 9.2.5. Intas
    • 9.2.6. Sandoz
    • 9.2.7. Stada Arzneimittel
    • 9.2.8. Teva

10. Future Outlook

List of Figures:

  • Figure 3-1: Global - Biologics Market (Billion US$), 2014-2020
  • Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products
  • Figure 3-3: Global - Biologics Market by Segment (%), 2014
  • Figure 4-1: Global - Biosimilars Market (Billion US$), 2014-2020
  • Figure 4-2: Global - Biosimilars Market by Key Geographies (%), 2014
  • Figure 4-3: Global - Biosimilars Market by Key Geographies (%), 2020
  • Figure 4-4: Global - Biosimilars Market by Key Segment (%), 2014
  • Figure 4-5: Global - Biosimilars Market by Key Segment (%), 2020
  • Figure 4-6: Global - Erythropoietin Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-7: Global - HGH Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-8: Global - G-CSF Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-9: Global - mAb Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-10: Global - Insulin Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-11: Global - Interferon Biosimilars Market (Million US$), 2014 & 2020
  • Figure 4-12: Europe - Biosimilars Market (Million US$), 2014-2020
  • Figure 4-13: Europe - Biosimilars Market by Country (%), 2014
  • Figure 4-14: Asia - Pacific - Biosimilars Market (Billion US$), 2014-2020
  • Figure 4-15: Others - Biosimilars Market (Billion US$), 2014-2020
  • Figure 5-1: World's Best Selling Biologics and their Patent Expiry in the US
  • Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014
  • Figure 9-2: Hospira - Breakdown of Revenue by Geographic Segment (%), 2014
  • Figure 9-3: Hospira - Breakdown of Revenue by Industry Segment (%), 2014
  • Figure 9-4: Sandoz - Global Sales (Billion USD), 2011-2013
  • Figure 9-5: Sandoz - Breakdown of Revenue by Geographic Segment (%),2013
  • Figure 9-6: Stada - Breakdown of Revenue by Industry Segment (%), 2014
  • Figure 9-7: Teva - Breakdown of Revenue by Geographic Segment (%), 2014

List of Tables:

  • Table 4-1: Global - Patent Expiry Status of EPOs
  • Table 4-2: Global - Biosimilar EPOs Approved for Marketing
  • Table 4-3: Global - Biosimilar EPOs in Pipeline
  • Table 4-4: Global - Biosimilar HGH Approved for Marketing
  • Table 4-5: Global - Biosimilar HGH in Pipeline
  • Table 4-6: Global - Biosimilar G-CSF Approved for Marketing
  • Table 4-7: Global - Biosimilar G-CSF in Pipeline
  • Table 4-8: Global - Patent Expiry Status of G-CSF
  • Table 4-9: Global - Biosimilar mAbs Approved for Marketing
  • Table 4-10: Global - Biosimilar mAbs in Pipeline
  • Table 4-11: Global - Patent Expiry Status of mAbs
  • Table 4-12: Global - Biosimilar Insulin Approved for Marketing
  • Table 4-13: Global - Biosimilar Insulin in Pipeline
  • Table 4-14: Global - Patent Expiry Status of Insulin
  • Table 4-15: Global - Biosimilar Interferons Approved for Marketing
  • Table 4-16: Global - Biosimilar Interferons in Pipeline
  • Table 4-17: Global - Patent Expiry Status of Interferons
  • Table 7-1: Global - Major M&A Activity in the Past Year
  • Table 9-1: Biocad - Biosimilars Approved for Marketing
  • Table 9-2: Biocad - Biosimilars in Pipeline
  • Table 9-3: Celltrion - Key Financials (Million KRW), 2011-2013
  • Table 9-4: Celltrion - Biosimilars Approved for Marketing
  • Table 9-5: Celltrion - Biosimilars in Pipeline
  • Table 9-6: Dong-A Pharmaceutical - Key Financials (Billion Won), 2011-2013
  • Table 9-7: Dong-A Pharmaceutical - Biosimilars in Pipeline
  • Table 9-8: Hospira - Key Financials (Million Dollars), 2012-2014
  • Table 9-9: Hospira - Biosimilars Approved for Marketing
  • Table 9-10: Hospira - Biosimilars in Pipeline
  • Table 9-11: Intas - Biosimilars Approved for Marketing
  • Table 9-12: Intas - Biosimilars in Pipeline
  • Table 9-13: Sandoz - Biosimilars Approved for Marketing
  • Table 9-14: Sandoz - Biosimilars in Pipeline
  • Table 9-15: Stada - Key Financials (Million Euros), 2012-2014
  • Table 9-16: Stada - Biosimilars Approved for Marketing
  • Table 9-17: Stada - Biosimilars in Pipeline
  • Table 9-18: Teva - Key Financials (Million Dollars), 2012-2014
  • Table 9-19: Teva - Biosimilars Approved for Marketing
Back to Top